WIRE - Novel Treatments in Renal Cell Cancer

Inclusion Criteria Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Aged ≥18 years and over. * Predicted life expectancy ≥ 16 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. * Have biopsy proven clear cell RCC, either as part of the screening process or if undertaken prior to screening no more than 6 weeks prior to consent. * Allow access to archival Formalin-Fixed Paraffin-Embedded (FFPE) tumour tissue from any previous renal tumour biopsy * Have a surgically resectable tumour as determined by the treating urologist * T1b or above, N0 and M0; OR have any T status where either N1 or M1 (but the participant must be deemed suitable for cytoreductive nephrectomy at time of enrolment). * No prior exposure to PARP inhibitors (including but not limited to olaparib), tyrosine kinase inhibitors (including but not limited to cediranib, sunitinib, pazopanib, axitinib, bevacizumab and cabozantinib), immunotherapy or immune checkpoint inhibitors (including but not limited to other anti-CTLA-4, anti-TIGIT, anti-PD-1, or anti-PD-L1 antibodies), nor prior treatment with a mammalian target of rapamycin (mTOR) inhibitor (including, but not limited to everolimus, temsirolimus, or sirolimus). Prior cytokine therapy (e.g. IL-2, IFN-α) or treatment with cytotoxics is NOT allowed. * At least 1 measurable lesion according to RECIST Version 1.1 at screening that can be accurately assessed at screening by MRI and is suitable for repeated assessment. A previously irradiated lesion cannot be considered a target lesion. Radiographic disease assessment can be performed up to 28 days prior to the first dose of trial treatment. It is acceptable for the measurable lesion to be planned for removal at surgery. CT reported RECIST assessments are acceptable at screening for participants with chest metastases. * Have adequate organ and marrow function, as defined below (measured within 28 days of first dose of trial medication): o Haemoglobin ≥ 90 g/L * Platelet count ≥ 100 x 109/L * Neutrophil count ≥ 1.5 x 109/L Creatinine clearance ≥45mL/min (calculated by Cockcroft and Gault equation: where estimated creatinine clearance = (140-age\[years\]) x weight (kg) (xF)a serum creatinine (mg/dL) x 72a where F=0.85 for females and 1 for males). Participants with 2+ proteinuria on dipstick must also have UPC \<0.5 on 2 consecutive samples. * Adequate hepatic function: * Alanine Aminotransferase (ALT) (SGPT) ≤2.5x the institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be ≤5x the institutional ULN, AND. * AST ≤2.5x the institutional ULN unless liver metastases are present, in which case it must be ≤5x the institutional ULN, AND. * Total bilirubin ≤1.5x the institutional ULN unless in the presence of known or suspected Gilbert's syndrome- the inclusion of potential participants with known/suspected Gilbert's syndrome must be discussed with the Trial Oncologist prior to their inclusion in the trial. For patients with known Gilbert's syndrome the threshold for receiving rilvegostomig/volrustomig is total bilirubin ≤ 1.5x the institutional ULN. * Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal participants. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \<50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). * Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). * For women of childbearing potential, a negative serum pregnancy test must be performed within 14 days of trial treatment and confirmed prior to treatment on Day 1. * Male participants must be willing to use a condom during treatment and for 3 months after the last dose of trial treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female participants and female partners of male participants should also be willing to use a highly effective form of contraception (see Section 11.8for acceptable methods) if they are of childbearing potential. * Participant is willing and able to comply with the protocol for the duration of the trial. * Adequately controlled thyroid function, with no symptoms of thyroid dysfunction SPECIFIC INCLUSION CRITERIA FOR OLAPARIB CONTAINING ARMS: * Haemoglobin must be ≥ 100 g/L * If abnormalities in the Full Blood Count (and it is clinically indicated): Peripheral blood smear with no features of myelodysplastic syndrome or acute myeloid leukaemia * Serum creatinine must be ≤1.5x the institutional ULN concurrent with creatinine clearance ≥51mL/min (calculated by Cockcroft and Gault equation as above) or based on a 24-hour urine creatinine clearance test. SPECIFIC INCLUSION CRITERIA FOR OLAPARIB PLUS CEDIRANIB ARM ONLY: • Urine protein: creatinine ratio (UPC) ≤1 OR ≤2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart. Patients with ≥2+ proteinuria on dipstick must also have UPC \<0.5 on 2 consecutive samples (ensure that the units for the protein and creatinine measurements are in the same units before calculating this ratio e.g., both